Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group
about
Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer.Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.Breast cancer: from "maximum tolerable" to "minimum effective" treatmentIs axillary clearance the standard of care for breast cancer patients with sentinel node involvement?Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?
P2860
Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Clinical trials update of the ...... of Cancer Breast Cancer Group
@ast
Clinical trials update of the ...... of Cancer Breast Cancer Group
@en
Clinical trials update of the ...... of Cancer Breast Cancer Group
@nl
type
label
Clinical trials update of the ...... of Cancer Breast Cancer Group
@ast
Clinical trials update of the ...... of Cancer Breast Cancer Group
@en
Clinical trials update of the ...... of Cancer Breast Cancer Group
@nl
prefLabel
Clinical trials update of the ...... of Cancer Breast Cancer Group
@ast
Clinical trials update of the ...... of Cancer Breast Cancer Group
@en
Clinical trials update of the ...... of Cancer Breast Cancer Group
@nl
P2093
P2860
P921
P356
P1476
Clinical trials update of the ...... of Cancer Breast Cancer Group
@en
P2093
Emiel J T Rutgers
Hervé Bonnefoi
Philip Meijnen
P2860
P2888
P356
10.1186/BCR906
P407
P577
2004-06-16T00:00:00Z
P5875
P6179
1034460607